• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

犬麻醉进展:基于生理的药代动力学模型预测肝功能损害犬的丙泊酚血浆浓度曲线

Advances in Canine Anesthesia: Physiologically Based Pharmacokinetic Modeling for Predicting Propofol Plasma Profiles in Canines with Hepatic Impairment.

作者信息

Gonzaga Lucas Wamser Fonseca, Egito Beatriz Monte, Coelho João Bosco Costa, Souza Gabriela Pereira, Martins Frederico Severino, Ferrante Marcos

机构信息

Department of Veterinary Medicine, Universidade Federal de Lavras, Lavras 37200-900, MG, Brazil.

Department of Clinical and Toxicological Analysis, Faculty of Pharmaceutical Sciences, Universidade de São Paulo, Av. Prof. Lineu Prestes, 580, Bl. 13B, São Paulo 05508-000, SP, Brazil.

出版信息

Pharmaceuticals (Basel). 2024 Dec 19;17(12):1720. doi: 10.3390/ph17121720.

DOI:10.3390/ph17121720
PMID:39770561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11678225/
Abstract

: A PBPK model allows the prediction of the concentration of drug amounts in different tissues and organs over time and can be used to simulate and optimize different therapeutic protocols in healthy and sick individuals. The objective of this work was to create a PBPK model to predict propofol doses for healthy canines and canines with hepatic impairment. : The study methodology was divided into two major phases, in which the first phase consisted of creating the PBPK model for healthy canines, and in the second phase, this model was adjusted for canines with hepatic impairment. The model for healthy canines presented good predictive performance, evidenced by the value of the performance measure of the geometric mean fold error that ranged from 0.8 to 1.25, meeting the double error criterion. The simulated regimen for healthy canines, i.e., of 5 mg/kg (administered as a bolus) followed by a continuous infusion at a rate of 0.13 mg/kg/min, was sufficient and ensured that all simulated subjects achieved the target plasma concentration. Canines with 60% and 40% liver function had infusion rate adjustments to ensure that individuals did not exceed the therapeutic window for maintenance of anesthesia. : The results presented in this manuscript are suggestive of the effectiveness and practicality of a PBPK model for propofol in canines, with a particular focus on hepatic impairment.

摘要

一个生理药代动力学(PBPK)模型能够预测不同组织和器官中药物量随时间的浓度变化,可用于模拟和优化健康个体及患病个体的不同治疗方案。本研究的目的是创建一个PBPK模型,以预测健康犬和肝功能受损犬的丙泊酚剂量。:研究方法分为两个主要阶段,第一阶段包括为健康犬创建PBPK模型,第二阶段针对肝功能受损犬对该模型进行调整。健康犬的模型表现出良好的预测性能,几何平均倍数误差性能指标值在0.8至1.25之间,证明符合双重误差标准。健康犬的模拟给药方案,即5mg/kg(静脉推注),随后以0.13mg/kg/min的速率持续输注,是足够的,并确保所有模拟对象达到目标血浆浓度。肝功能分别为60%和40%的犬对输注速率进行了调整,以确保个体不超过维持麻醉的治疗窗。:本手稿中呈现的结果表明,犬用丙泊酚的PBPK模型具有有效性和实用性,尤其关注肝功能受损情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/f8cc8bbc6358/pharmaceuticals-17-01720-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/dbbf3786b86c/pharmaceuticals-17-01720-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/8b1e8284ce1f/pharmaceuticals-17-01720-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/55f9652a542a/pharmaceuticals-17-01720-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/b0e55d8f57ca/pharmaceuticals-17-01720-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/5f66dd30afe5/pharmaceuticals-17-01720-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/f8cc8bbc6358/pharmaceuticals-17-01720-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/dbbf3786b86c/pharmaceuticals-17-01720-g001a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/8b1e8284ce1f/pharmaceuticals-17-01720-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/55f9652a542a/pharmaceuticals-17-01720-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/b0e55d8f57ca/pharmaceuticals-17-01720-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/5f66dd30afe5/pharmaceuticals-17-01720-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/034c/11678225/f8cc8bbc6358/pharmaceuticals-17-01720-g006.jpg

相似文献

1
Advances in Canine Anesthesia: Physiologically Based Pharmacokinetic Modeling for Predicting Propofol Plasma Profiles in Canines with Hepatic Impairment.犬麻醉进展:基于生理的药代动力学模型预测肝功能损害犬的丙泊酚血浆浓度曲线
Pharmaceuticals (Basel). 2024 Dec 19;17(12):1720. doi: 10.3390/ph17121720.
2
Physiologically based pharmacokinetic modeling to predict the effect of risperidone on aripiprazole pharmacokinetics in subjects with different CYP2D6 genotypes and individuals with hepatic impairment.基于生理的药代动力学建模,以预测利培酮对不同CYP2D6基因型受试者及肝功能损害个体中阿立哌唑药代动力学的影响。
Ther Adv Drug Saf. 2024 Dec 18;15:20420986241303432. doi: 10.1177/20420986241303432. eCollection 2024.
3
Physiologically-Based Pharmacokinetic Modeling of Trofinetide in Moderate Renal Impairment for Phase 1 Clinical Study Dose Selection with Model Validation.用于1期临床研究剂量选择及模型验证的中度肾功能损害患者中曲非尼肽的基于生理的药代动力学建模
Eur J Drug Metab Pharmacokinet. 2025 Jan;50(1):23-38. doi: 10.1007/s13318-024-00924-1. Epub 2024 Nov 8.
4
Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations.基于生理的坎地沙坦药代动力学建模,以预测肝肾功能损害及老年人群的暴露情况。
Ther Adv Drug Saf. 2023 Dec 25;14:20420986231220222. doi: 10.1177/20420986231220222. eCollection 2023.
5
The performance of compartmental and physiologically based recirculatory pharmacokinetic models for propofol: a comparison using bolus, continuous, and target-controlled infusion data.隔室和基于生理的丙泊酚再循环药代动力学模型的性能:使用推注、连续和靶控输注数据的比较。
Anesth Analg. 2010 Aug;111(2):368-79. doi: 10.1213/ANE.0b013e3181bdcf5b. Epub 2009 Oct 27.
6
Human physiologically based pharmacokinetic model for propofol.丙泊酚的人体生理药代动力学模型。
BMC Anesthesiol. 2005 Apr 22;5(1):4. doi: 10.1186/1471-2253-5-4.
7
Predicting In Vivo Target Occupancy (TO) Profiles via Physiologically Based Pharmacokinetic-TO Modeling of Warfarin Pharmacokinetics in Blood: Importance of Low Dose Data and Prediction of Stereoselective Target Interactions.通过基于生理的药代动力学-目标结合模型预测华法林在血液中的体内目标占有率(TO)谱:低剂量数据的重要性和立体选择性靶相互作用的预测。
Drug Metab Dispos. 2023 Sep;51(9):1145-1156. doi: 10.1124/dmd.122.000968. Epub 2023 Mar 13.
8
Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling.应用全身体生理药代动力学模型模拟健康成年人和肾功能受损患者比索洛尔的药代动力学。
Acta Pharmacol Sin. 2012 Nov;33(11):1359-71. doi: 10.1038/aps.2012.103. Epub 2012 Oct 22.
9
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling.采用基于生理的药代动力学模型模拟非布司他在健康受试者和肾功能受损患者中的药代动力学。
Biopharm Drug Dispos. 2022 Aug;43(4):140-151. doi: 10.1002/bdd.2325. Epub 2022 Jul 4.
10
Daptomycin Physiology-Based Pharmacokinetic Modeling to Predict Drug Exposure and Pharmacodynamics in Skin and Bone Tissues.达托霉素基于生理学的药代动力学模型预测皮肤和骨骼组织中的药物暴露和药效学。
Clin Pharmacokinet. 2022 Oct;61(10):1443-1456. doi: 10.1007/s40262-022-01168-5. Epub 2022 Aug 16.

引用本文的文献

1
The Innovation Paradox in Emerging Pharmaceutical Markets: Barriers and Opportunities for Sustainable Development.新兴制药市场中的创新悖论:可持续发展的障碍与机遇
Pharm Res. 2025 May 29. doi: 10.1007/s11095-025-03856-w.

本文引用的文献

1
Integration of artificial neural network and physiologically based biopharmaceutic models in the development of sustained-release formulations.人工神经网络与基于生理的生物药剂学模型在缓控释制剂开发中的整合。
Biopharm Drug Dispos. 2023 Aug;44(4):335-343. doi: 10.1002/bdd.2376. Epub 2023 Aug 30.
2
Physiologically based pharmacokinetic modelling to inform combination dosing regimens of ceftaroline and daptomycin in special populations.基于生理的药代动力学建模,以指导特殊人群中头孢洛林和达托霉素的联合给药方案。
Br J Clin Pharmacol. 2023 Sep;89(9):2726-2738. doi: 10.1111/bcp.15731. Epub 2023 May 11.
3
The Impact of Low Cardiac Output on Propofol Pharmacokinetics across Age Groups-An Investigation Using Physiologically Based Pharmacokinetic Modelling.
低心输出量对不同年龄组丙泊酚药代动力学的影响——一项基于生理药代动力学模型的研究
Pharmaceutics. 2022 Sep 16;14(9):1957. doi: 10.3390/pharmaceutics14091957.
4
An Interactive Generic Physiologically Based Pharmacokinetic (igPBPK) Modeling Platform to Predict Drug Withdrawal Intervals in Cattle and Swine: A Case Study on Flunixin, Florfenicol, and Penicillin G.一种交互式通用生理药代动力学(igPBPK)建模平台,用于预测牛和猪的停药期:以氟尼辛、氟苯尼考和青霉素 G 为例。
Toxicol Sci. 2022 Jul 28;188(2):180-197. doi: 10.1093/toxsci/kfac056.
5
PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.COVID-19合并肝病患者地塞米松的生理药代动力学建模
Front Pharmacol. 2022 Jan 28;13:814134. doi: 10.3389/fphar.2022.814134. eCollection 2022.
6
Obesity and anesthetic pharmacology: simulation of target-controlled infusion models of propofol and remifentanil.肥胖与麻醉药理学:丙泊酚和瑞芬太尼靶控输注模型的模拟。
Korean J Anesthesiol. 2021 Dec;74(6):478-487. doi: 10.4097/kja.21345. Epub 2021 Aug 18.
7
Pharmacokinetic concepts for dexmedetomidine target-controlled infusion pumps in children.儿童人群中右美托咪定靶控输注泵的药代动力学概念。
Paediatr Anaesth. 2021 Sep;31(9):924-931. doi: 10.1111/pan.14235. Epub 2021 Jun 24.
8
Physiologically-Based Pharmacokinetic (PBPK) Modeling Providing Insights into Fentanyl Pharmacokinetics in Adults and Pediatric Patients.基于生理的药代动力学(PBPK)模型为深入了解芬太尼在成人和儿科患者中的药代动力学提供了依据。
Pharmaceutics. 2020 Sep 23;12(10):908. doi: 10.3390/pharmaceutics12100908.
9
Total Intravenous Anesthesia for the Small Animal Critical Patient.小动物危重症患者的全静脉麻醉。
Vet Clin North Am Small Anim Pract. 2020 Nov;50(6):1433-1444. doi: 10.1016/j.cvsm.2020.07.007. Epub 2020 Aug 20.
10
Target-controlled-infusion models for remifentanil dosing consistent with approved recommendations.符合批准建议的瑞芬太尼靶控输注模型。
Br J Anaesth. 2020 Oct;125(4):483-491. doi: 10.1016/j.bja.2020.05.051. Epub 2020 Jul 9.